×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: Coronavirus | Financial Markets | Health Topics | Money | Vaccines | CureVac | GSK

CureVac to Withdraw First-Generation COVID-19 Vaccine Candidate

CureVac
(AP)

Tuesday, 12 October 2021 07:32 AM

CureVac will withdraw its first-generation COVID-19 vaccine candidate and focus on collaborating with GSK to develop second-generation mRNA vaccine technology instead, the Germany-based biotechnology company said on Tuesday.

The company said it will withdraw its first-generation vaccine candidate CVnCoV, which failed late-stage trials with 47% accuracy in June, due to a potential overlap with approval timelines for a second-generation candidate.

The earliest potential approval of CVnCoV would have come in the second quarter of 2022 when the candidates from the second-generation vaccine program are expected to progress to late-stage clinical development by that time, CureVac said.

© 2021 Thomson/Reuters. All rights reserved.


StreetTalk
CureVac will withdraw its first-generation COVID-19 vaccine candidate and focus on collaborating with GSK to develop second-generation mRNA vaccine technology instead, the Germany-based biotechnology company said on Tuesday.
CureVac, GSK, COVID-19 vaccination
96
2021-32-12
Tuesday, 12 October 2021 07:32 AM
Newsmax Media, Inc.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
TOP

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved